2004 to 2000 Design and project managementConsulting Services Lemoore, CA Apr 2014 to Jul 2014 Director of Facilities (contract)Consulting Services Eagle Pass, TX Oct 2011 to Jul 2013 Director of Facilities (contract)Consulting Services Geyserville, CA May 2008 to Mar 2009 Director of FacilitiesConsulting Services Detroit, MI Feb 2006 to May 2008 Director of FacilitiesConsulting Services San Diego, CA Oct 2005 to Nov 2005 Capital Project ManagerLegends Casino Toppenish, WA Feb 2003 to Apr 2004 Director of FacilitiesGeneral Motors Moraine, OH Mar 1999 to Jan 2002 Regional Facilities EngineerHOK/K Engineering Dayton, OH Oct 1994 to Mar 1996 Director, Engineering & Technical ServicesLockwood Greene Engineers Cincinnati, OH Oct 1990 to Oct 1994 Project ManagerBBS Corporation Cincinnati, OH Sep 1988 to Oct 1990 Lead ArchitectPharmaceutical and Food Cincinnati, OH Mar 1986 to Mar 1988 Corporate EngineerMerrell Dow Pharmaceuticals Cincinnati, OH Jun 1978 to Mar 1986 Project EngineerArchitecture Hamilton, OH Nov 1975 to Jun 1978 Pease Company - Designer
Education:
Central Western University Arlington, TX 2000 MBA in FinanceITT Technical Institute Dayton, OH 1975 Architectural Design and EngineeringReading High School Reading, OH 1973University of Cincinnati Cincinnati, OH BSME in Mechanical Engineering
Us Patents
Novel Compounds Of Proline And Morpholine Derivatives
Hengmiao Cheng - San Diego CA, US Stephan Cripps - San Diego CA, US Klaus Dress - San Diego CA, US Jacqui Hoffman - San Diego CA, US Buwen Huang - San Diego CA, US Stanley Kupchinsky - San Diego CA, US Phuong Le - San Diego CA, US Sajiv Nair - Vista CA, US Timothy Parrott - Carlsbad CA, US Christopher Smith - San Diego CA, US Yong Wang - San Diego CA, US Yi Yang - San Diego CA, US
The present invention relates to compounds with the formulas (I), (II), and (III), or a pharmaceutically acceptable salt thereof: wherein T is a (4 to 10)-membered heterocyclyl selected from the group consisting of and wherein R, Rand Rare as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formulas (I), (II), and (III) and methods of treating a condition that is mediated by the modulation of the 11-β-hsd-1 enzyme, the method comprising administering to a mammal an effective amount of a compound of formulas (I), (II), and (III).